Key clinical point: A single 19 Gy high-dose rate (HDR) brachytherapy may be beneficial for patients with low-risk and favorable intermediate-risk localized prostate cancer, but not for unfavourable intermediate- and high-risk patients.
Major finding: The 3-year biochemical progression-free survival rate in low-, favorable intermediate-, unfavourable intermediate-, and high-risk patients was 100%, 89%, 81%, and 75%, respectively; P = .04 for differences between groups).
Study details: The data come from a prospective study of 441 patients with localized prostate cancer, conducted at 7 centres across the UK.
Disclosures: Central database maintenance for the study was funded by Varian Medical Systems Ltd. Further support was provided by Mount Vernon Marie Curie Research Fund. Hannah Tharmalingam was partly funded by Prostate Cancer UK and Peter J. Hoskin was supported by NIHR Manchester Biochemical Research Centre. The authors declared no personal or financial conflicts of interest.
Tharmalingam H et al. Radiother Oncol. 2020 Feb 7. doi: 10.1016/j.radonc.2019.12.017.